|
Mountain View, California, October 15, 2003 – SurroMed, Inc. today announced
that it has entered into a collaboration agreement with the Comprehensive
Cancer Center of Wake Forest University. Wake Forest and SurroMed will collaborate
on the collection and analysis of clinical samples in prostate and renal cell cancer.
“We are pleased to establish this relationship with Wake Forest, one of the country’s leading cancer research centers. This collaboration will involve a portion of the
cancer targets that we acquired in our previously announced transaction with PPD, Inc.,”
said Gordon Ringold, Ph.D., CEO and Chairman of SurroMed. “This is the first step in
our program to develop novel cancer diagnostics based on differential protein and
metabolite profiling.”
“The Comprehensive Cancer Center looks forward to working closely with SurroMed,
the leader in the field of biomarker discovery. Together we intend to develop novel
diagnostic products for these important cancers,” said Frank Torti, MD, Director of
the Comprehensive Cancer Center of Wake Forest University.
SurroMed’s integrated biomarker discovery program combines proprietary sample
preparation techniques with advanced high-resolution mass spectrometric methods for
the differential analysis of biological samples. Subsequently, detailed bioanalytical
data is analyzed and mined using SurroMed’s suite of informatics tools. Biomarker
analysis and profiling has multiple applications across all stages of drug discovery
and development from preclinical analysis of animal samples to follow-up evaluation of patients already receiving marketed products.
About SurroMed, Inc. - The Biomarker Company
SurroMed is pioneering biomarker enabled drug discovery and development. The company
focuses on discovering and applying biomarkers to improve the drug discovery and
development process and enable the precise diagnosis and personalized treatment of
disease. SurroMed's research process yields biological markers and information that
enable accelerated, cost-efficient discovery and development of new therapeutic products,
as well as development of diagnostic tests for early disease detection, disease staging,
patient stratification, and guiding and monitoring therapy.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Ian McConnell, Ph.D
Senior Account Executive
(415) 677-4455 ext. 233
email: [email protected]
|